Immunovant, Inc. (IMVT) Stock: Price, Forecast & Analyst Target
Immunovant, Inc. (IMVT) — MoonshotScore 25/100 (Weak band), calculated Nov 18, 2026. Price $32.52 (-1.96%), as of the Nov 19, 2026 trading session; market cap $6.73B. Expected results Feb 5, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 9.32× (cash as of Sep 30, 2026) · expected results Feb 5, 2027
Immunovant, Inc. · IMVT · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13 (results through Q1 FY2027; the quarter ended Sep 2026 not covered): Immunovant develops antibody therapies for autoimmune disease, led by batoclimab, which blocks FcRn to alter a disease-relevant immune mechanism. Its value depends on whether clinical progress can justify heavy research spending before the cash runway becomes restrictive.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Immunovant (IMVT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — bottom-tier quality underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Fading; Momentum: Rising.
- EPS beat 0 of the last 4 reports
- Altman Z 34.53 · Piotroski F 2
- ROE -63.0% · ROA -66.9% · current ratio 7.31 · earnings yield -7.4% · free-cash-flow yield -5.7%
Holding back: weak fundamentals, soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $32.52 | |
| Change on the day | -1.96% | |
| 52-week range | $21.86–$45.42 | |
| Market capitalisation | $6.73B | — |
| Price / earnings (trailing) | -10.36 | |
| Shares traded on the day | 731.0K | |
| Beta (volatility vs the S&P 500) | 0.84 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Immunovant (IMVT): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Immunovant (IMVT), and what does it report?
Short answer · as of
This is a clinical-development biotechnology company, not a commercial drugmaker with recurring product demand. Batoclimab is the primary program described, with development spanning myasthenia gravis, thyroid eye disease and warm autoimmune hemolytic anemia.
Research dated 2026-09-13 (results through Q1 FY2027; the quarter ended Sep 2026 not covered).
Reported losses and cash outflows therefore measure the cost of advancing the pipeline more directly than commercial performance. A modest revenue entry appeared in the latest quarter after annual periods without revenue, but that change alone does not establish a recurring product-sales business.
What do the latest results show for Immunovant (IMVT)?
Research dated 2026-09-13 (results through Q1 FY2027; the quarter ended Sep 2026 not covered).
The latest results show research spending holding near its newly elevated level, while operating and net losses widened from the preceding period. Operating cash use also increased, confirming that the heavier development expense is translating into a faster drain on liquidity.
Reported revenue matched the corresponding estimate, yet the loss was worse than expected. The financial record supports the spending increase and wider loss, but it does not identify the revenue source or attribute the change to a management explanation.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $0.00 Sep 30, 2026
- Latest quarter · R&D
- $85.01M Sep 30, 2026
- Latest quarter · SG&A
- $19.14M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$104.16M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $0.00 | $85.01M | $19.14M | −$104.16M |
| Jun 30, 2026 | $7.09M | $142.63M | $17.69M | −$153.23M |
| Mar 31, 2026 | $0.00 | $142.29M | $17.27M | −$159.55M |
| Dec 31, 2025 | $0.00 | $98.92M | $15.44M | −$114.36M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · EPS vs estimate
- Above estimate Nov 9, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 9, 2026 | Not available | Not available | −$0.4700 | −$0.7370 |
| Aug 6, 2026 | $7.09M | $7.09M | −$0.7500 | −$0.6289 |
| May 20, 2026 | Not available | Not available | −$0.7300 | −$0.5920 |
| Feb 6, 2026 | Not available | $6.00M | −$0.6100 | −$0.7200 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $0 | -$97M | -$0.47 (diluted) |
| Q1 FY2027 | $7M | -$153M | -$0.75 (diluted) |
| Q4 FY2026 | $0 | -$148M | -$0.73 (diluted) |
| Q3 FY2026 | $0 | -$111M | -$0.61 (diluted) |
What are the financial strengths and risks for Immunovant (IMVT)?
Short answer
Cash and short-term investments were $722.27M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$83.21M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13 (results through Q1 FY2027; the quarter ended Sep 2026 not covered).
Immunovant carries no reported debt and holds cash and short-term investments well above total liabilities. That gives the clinical program meaningful financial flexibility without near-term debt service competing for research capital.
The protection is finite. Operations consistently consume cash, the latest outflow accelerated, and the cash balance has declined across recent periods following an earlier increase. At the recent spending pace, funding risk can return before a long clinical and commercialization timetable is complete.
Market value also stands far above net cash, so the equity case reflects substantial value assigned to future program outcomes rather than balance-sheet assets. Weak clinical evidence, delays or continued spending without corresponding progress would pressure that premise.
Data-derived red flags
- Negative return on equity (-63.0%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$83.21M Sep 30, 2026
- Previous quarter · operating cash flow
- −$124.40M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$83.21M | $0.00 |
| Jun 30, 2026 | −$124.40M | $0.00 |
| Mar 31, 2026 | −$95.06M | −$10,000 |
| Dec 31, 2025 | −$92.32M | $0.00 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Immunovant (IMVT)?
Short answer · as of
The next earnings report is expected on Feb 5, 2027.
Research dated 2026-09-13 (results through Q1 FY2027; the quarter ended Sep 2026 not covered).
The next earnings release should be read for recurrence of the recent revenue entry, movement in research expense and the pace of operating cash use. Repeating revenue without clarification of its source would still provide limited evidence about commercial demand, while another rise in burn would shorten the financial margin for clinical execution.
Longer-range estimates assume revenue expands substantially before earnings turn positive. Progress that broadens the expected revenue base while containing research and administrative costs would support that path; estimate slippage alongside falling cash would weaken it.
How does Immunovant compare with its peers?
Short answer
Immunovant's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q1 FY2027; the quarter ended Sep 2026 not covered).
Immunovant differs from diversified biotechnology companies because its business is centered on a clinical antibody program aimed at FcRn rather than an established portfolio of marketed products. Research expense dominates the operating structure, while capital expenditure is negligible, making clinical development the principal use of cash.
That structure concentrates both upside and failure risk in evidence generated by the autoimmune pipeline. Comparisons based on sales multiples or gross margin offer little insight while reported revenue remains minimal and recurring product economics are unproven.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $286.94 Nov 19, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $3.08B | 68 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| $124.39 Nov 19, 2026 | $5.25B | 66 5-pillar Nov 18, 2026 | |
| $151.02 Nov 19, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| $310.90 Nov 19, 2026 | $8.69B | 60 5-pillar Nov 18, 2026 | |
| Immunovant (IMVT) — this page | $32.52 | $6.73B | 25 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $40.00 – $40.00
- Consensus target
- $40.00
- Median target
- $40.00
Consensus record · Captured .
Measured against a quoted price of $32.52 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 11, 2026
- Transactions
- 63
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 35
- Other transactions
- 28
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 53.0% Period end Sep 30, 2026
- Previous quarter · ownership
- 54.0% Prior to period end Sep 30, 2026
- Reporting holders
- 245 Period end Sep 30, 2026
- Previous quarter · holders
- 240 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 15,704,154 |
| Deep Track Capital, LP | 9,160,801 |
| Blackrock, INC. | 7,425,771 |
| Farallon Capital Management, L.L.C. | 6,471,000 |
| Morgan Stanley | 5,684,840 |
Tracked investors
Which of the 16 named investors we follow held IMVT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IMVT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Immunovant (IMVT)?
Common Questions About IMVT (Healthcare)
Research dated 2026-09-13 (results through Q1 FY2027; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is Immunovant’s batoclimab designed to do?
Batoclimab is a fully human monoclonal antibody designed to target and block FcRn, a mechanism implicated in autoimmune disease. Its development includes myasthenia gravis, thyroid eye disease and warm autoimmune hemolytic anemia.
Does Immunovant’s reported revenue mean batoclimab is commercial?
Immunovant remains a clinical-development company, while the latest quarter contains a modest revenue entry after annual periods with none. That entry does not by itself demonstrate recurring batoclimab product sales.
Can Immunovant fund batoclimab development from operating cash?
Operations consume cash rather than generate it, so development is funded from existing liquidity and any future financing or other capital sources. The debt-free balance sheet provides room, but the recent burn rate leaves a finite runway.
How concentrated is Immunovant’s spending on its autoimmune pipeline?
Research expense is the dominant reported operating cost and has risen materially across annual periods. The latest quarterly pattern shows that elevated research commitment continuing while administrative expense remains much smaller.
What is the IMVT stock price today?
The last price recorded for Immunovant, Inc. (IMVT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the IMVT price target?
The analyst consensus price target for Immunovant, Inc. (IMVT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 72 figures on this page — 1 from SEC filings and earnings calls, 65 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com